$GHRS News
Last published 3mo ago
- 3mo agoGHRSGH Research Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAlignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results in postpartum
- 3mo agoHELPCMPSGHRSDFTX+1A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps WideningPR NewswireUSA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. ...
- 3mo agoLLYDFTXCMPSHELP+4The market for psychedelic drugs to treat mental health conditions gets a big buy signalCNBCEli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
- 3mo agoHELPLLYATAICMPS+2Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real TimePR NewswireFor half a century, psychedelic medicine was the field serious money would not touch. That ended this morning. Eli Lilly and Company (NYSE: LLY)...
- 4mo agoHELPDFTXCMPSGHRS+1Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityGlobeNewswireNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on
- 4mo agoHELPCMPSDFTXGHRSA Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This YearPR NewswireUSA News Group News Commentary, In drug development, enrollment is the quiet variable that decides whether a promising therapy ever reaches a data...
- 5mo agoGHRSGH Research Announces Publication of Phase 2a Postpartum Depression ResultsGlobeNewswireDUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral
- 6mo agoGHRSGH Research Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePhase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study enrolment completedCash,
- 6mo agoGHRSGH Research Announces Pricing of $117.5 Million Underwritten OfferingGlobeNewswireDUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 6mo agoGHRSGH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental IllnessGlobeNewswireDUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 7mo agoGHRSGH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRDGlobeNewswirePhase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior
- 8mo agoHELPCMPSATAIDFTX+1CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA DecisionsPR NewswireThe central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance through late-stage trials...
- 8mo agoGHRSGH Research Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireCompleted Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash, cash equivalents and
- 8mo agoHELPATAIDFTXGHRS+1Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsPR NewswireEquity-Insider.com News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant...
- 10mo agoGHRSGH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026GlobeNewswireGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan.
- 10mo agoGHRSGH Research to Announce IND Status for GH001GlobeNewswireDUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 1y agoGHRSGH Research Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireEngagement with FDA on GH001 IND complete response ongoingFull dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025Long-term clinical data on safety and efficacy from Open-Label Extension
- 1y agoGHRSGH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP CongressGlobeNewswireDUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 1y agoGHRSGH Research Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireGlobal pivotal program initiation on track for 2026Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent
- 1y agoGHRSGH Research Announces Global Pivotal Program Plans and Further Development UpdatesGlobeNewswireEngagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment was
- 1y agoGHRSGH Research Submits Complete IND Hold Response to FDA Ahead of ScheduleGlobeNewswireDUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 1y agoGHRSGH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual MeetingGlobeNewswireDUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 1y agoGHRSGH Research Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswirePrimary endpoint met in Phase 2b trial with GH001 in TRD demonstrating -15.5 Point placebo-adjusted MADRS reductionFull response to the IND hold on track for submission in mid-2025Cash, cash equivalents, other financial
- 1y agoGHRSGH Research Reports Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewswirePhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate proprietary aerosol
- 1y agoGHRSGH Research Announces Pricing of $150 Million Public OfferingGlobeNewswireDUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 1y agoGHRSGH Research Announces Proposed Public OfferingGlobeNewswireDUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
- 1y agoGHRSGH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS ReductionGlobeNewswirePrimary endpoint met, GH001 led to an ultra-rapid anti-depressant effect with a significant placebo-adjusted MADRS reduction from baseline of -15.5 on Day 8 (p<0.0001)The majority of the patients treated with GH001
- 1y agoGHRSGH Research to Provide Update on Phase 2b Trial with GH001 in TRDGlobeNewswireDUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced
- 1y agoGHRSGH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-RodentsGlobeNewswirePrimary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8Primary endpoint met in phase 2a POC
- 1y agoGHRSGH Research Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswirePhase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol delivery device in healthy
- 2y agoGHRSGH Research Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswirePhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and expected completion of 6-month open-label extension phase in Q1
- 2y agoGHRSGH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive OfficerGlobeNewswireDUBLIN, Ireland, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 2y agoGHRSGH Research Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswirePhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical
- 2y agoGHRSGH Research Reports Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewswirePhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum depression on track for
- 2y agoGHRSGH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant DepressionGlobeNewswireDUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 3y agoGHRSGH Research Reports Third Quarter Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 3y agoGHRSGH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant DepressionGlobeNewswireDUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 3y agoGHRSGH Research Reports Second Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 3y agoGHRSGH Research Reports First Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewswireDUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 3y agoGHRSGH Research Reports Full Year 2022 Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 3y agoGHRSGH Research Provides Business Updates and Highlights Key Upcoming MilestonesGlobeNewswireInitial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device for GH001 progressed, IND submission with this
- 4y agoGHRSGH Research Reports Third Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today
- 4y agoGHRSGH Research Reports Second Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the sec
- 4y agoGHRSGH Research Reports First Quarter 2022 Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the firs
- 4y agoGHRSGH Research Reports Full Year 2021 Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the f
- 4y agoATAICMPSCYBNGHRS+1Psychedelic Therapies Offer Hope for Mental HealthPR NewswireNEW YORK, March 2, 2022 /PRNewswire/ -- Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can't be overstated. Indeed, the inability of the nervous system to change its activity in response to stimuli often produces
- 4y agoGHRSGH Research Reports Third Quarter 2021 Financial Results and Provides Business UpdatesGlobeNewswireDUBLIN, Ireland, Dec. 06, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the thi
- 4y agoGHRSGH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant DepressionGlobeNewswirePrimary endpoint met in Phase 2 part of clinical trial for GH001 in TRD 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p<0.0001) Secondary endpoints met Mean change from baseline in MADRS at day 7 after dosing wa
- 5y agoGHRSGH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial ResultsGlobeNewswireDUBLIN, Ireland, Sept. 23, 2021 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided business updates and reporte